Brief: Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers
10/10/2024 21:11
Allakos Inc ALLK.O :
* ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS
AK006 IN
HEALTHY VOLUNTEERS
* ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY
PROFILE
* ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006
IN
PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025
Source text for Eikon: ID:nGNX8K0JFg
Further company coverage: ALLK.O
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences